Ozempic and Other GLP‑1 Drugs: All Hype or Actually Helpful?

A Guide to Weight Loss Medications for Benefits Brokers and Advisors

With a staggering 42% of adults grappling with obesity, the GLP‑1 receptor agonists have emerged as a promising trend. However, these medications can be costly. How can employers cope with these costs and enhance employee health? This guide will show you:

  • An overview of GLP‑1 drugs, which ones are approved for weight loss, and what clinical trial numbers say about effectiveness
  • Obesity prevalence by state
  • Plan parameters to consider